Octave Bioscience was founded to deliver an end-to-end care management platform for multiple sclerosis as well as a full range of neurodegenerative diseases. Its Comprehensive Care Platform is designed to provide neurologists and their patients with objective metrics to facilitate informed care and shared decision making for better patient outcomes.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/20/20 | $32,000,000 | Series B |
Blue Venture Fund Casdin Capital Deerfield Management Company, L.P. Echo Health Ventures Northpond Ventures  Section 32 | undisclosed |
| 07/26/23 | $30,000,000 | Series B Extension |
Blue Venture Fund Casdin Capital Deerfield Management Company, L.P. dRx Capital Echo Health Ventures Hikma Ventures Intermountain Ventures Merck Global Health Innovation Fund Northpond Ventures Section 32 | undisclosed |
